Health Care • Medical Specialities
$23.14 ▼ -2.74
(-10.61%)
MKT CAP: $2.20B • VOL: 4.95M
52W L $9 52W H $26
FTRE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.72B | $2.70B | $2.84B |
| YoY Revenue Growth % | +1.0% | -5.1% | — |
| Gross Profit | $1.20B | $1.19B | $1.25B |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$872.6M | -$161.9M | $32.0M |
| Operating Margin % | -32.0% | -6.0% | 1.1% |
| Net Income (GAAP) | -$989.0M | -$329.0M | -$25.0M |
| EBITDA (Normalized) | -$774.6M | -$64.8M | $134.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $113.5M | $262.8M | $168.4M |
| Capital Expenditures (CapEx) | $122.6M | $121.3M | $127.9M |
| Free Cash Flow (FCF) | -$9.1M | $141.5M | $40.5M |
| FCF Margin % | -0.3% | 5.2% | 1.4% |
| Return on Invested Capital (ROIC %) | -45.0% | -5.6% | 1.2% |
| Cash & Short-Term Equivalents | $174.6M | $118.5M | $375.2M |
| Total Debt (Short + Long Term) | $1.05B | $1.05B | $798.2M |
| Total Stockholders' Equity | $563.5M | $1.36B | $1.64B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FTRE.